Evaxion doses first patient in extension of phase 2 trial exploring the full potential of ai-designed personalized cancer vaccine evx-01

Copenhagen, denmark, may 22, 2025 - evaxion a/s (nasdaq: evax) (“evaxion”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, has dosed the first patient in its one-year extension of the ongoing phase 2 trial with its lead asset evx-01. designed with evaxion's ai-immunology™ platform, evx-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
EVAX Ratings Summary
EVAX Quant Ranking